Recombinant Human MGMT Protein，His

MGMT (O6-methylguanine-DNA methyltransferase) is a crucial DNA repair protein involved in the direct reversal of DNA damage caused by alkylating agents, which are commonly found in various environmental toxins and certain chemotherapeutic drugs like temozolomide. The research into MGMT has gained substantial attention due to its significant role in cancer biology, particularly in the context of glioblastoma and other malignancies where alkylating agents are utilized as treatment options. The activity of MGMT is associated with resistance to these therapies, as high levels of MGMT expression can lead to the effective repair of drug-induced DNA damage, resulting in treatment failure. Consequently, understanding the structural and functional dynamics of MGMT has become paramount for developing therapeutic strategies that can either inhibit its action or predict patient response to alkylating agent-based treatments. Recent studies have focused on the protein’s mechanism of action, regulation, and its potential as a biomarker for treatment outcomes. The exploration of MGMT’s structure and the effects of genetic polymorphisms on its activity have opened new avenues for targeted interventions and personalized medicine approaches in oncology, emphasizing the importance of MGMT not only in cancer treatment efficacy but also in the broader scope of DNA damage response and repair mechanisms.